Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 685

Results For "RI"

11153 News Found

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
News | May 11, 2024

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024


Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr
News | May 11, 2024

Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr

The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024


Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr
News | May 11, 2024

Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr

The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024


Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr
News | May 11, 2024

Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr

The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024


Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Drug Approval | May 10, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25


Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr
News | May 10, 2024

Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr

The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024


Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
News | May 10, 2024

Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr

The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024


Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
News | May 10, 2024

Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr

The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024


Cipla receives 1 observation from USFDA for Kurkumbh facility
Drug Approval | May 10, 2024

Cipla receives 1 observation from USFDA for Kurkumbh facility

The company is committed to address this observation comprehensively within stipulated time


Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
News | May 09, 2024

Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners

Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies